secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093951
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics Q2 net loss $74.1M; CFO Wilson departs; paltusotine NDA on track for H2 2024
--------------------------------------------------------------------------------

- Net loss of $74.1M in Q2 2024 vs $51.0M in Q2 2023; R&D expenses rose to $58.3M from $40.6M.
- CFO Marc Wilson stepping down for personal reasons; search for successor initiated; he will remain until replacement on-boarded.
- Paltusotine NDA for acromegaly on track for H2 2024; Phase 3 program for carcinoid syndrome expected to begin by end of 2024.
- Topline data from atumelnant Phase 2 studies in CAH and Cushing's syndrome anticipated by end of 2024.
- Unrestricted cash $863M as of June 30, 2024; management expects funding into 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000095017024093951/0000950170-24-093951-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000095017024093951/crnx-20240805.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093951

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer